HRP20120561T1 - Metil fenilsulfonil piperazin il h benzimidazol kao hidroksitriptaminski ligand - Google Patents

Metil fenilsulfonil piperazin il h benzimidazol kao hidroksitriptaminski ligand Download PDF

Info

Publication number
HRP20120561T1
HRP20120561T1 HRP20120561AT HRP20120561T HRP20120561T1 HR P20120561 T1 HRP20120561 T1 HR P20120561T1 HR P20120561A T HRP20120561A T HR P20120561AT HR P20120561 T HRP20120561 T HR P20120561T HR P20120561 T1 HRP20120561 T1 HR P20120561T1
Authority
HR
Croatia
Prior art keywords
disorder
compound
disorders
disease
cognitive
Prior art date
Application number
HRP20120561AT
Other languages
English (en)
Croatian (hr)
Inventor
Simon@N@@Haydar
Patrick@M@@Andrae
Heedong@Yun
Albert@J@@Robichaud
Original Assignee
Wyeth@LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120561(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth@LLC filed Critical Wyeth@LLC
Publication of HRP20120561T1 publication Critical patent/HRP20120561T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20120561AT 2008-11-11 2009-11-10 Metil fenilsulfonil piperazin il h benzimidazol kao hidroksitriptaminski ligand HRP20120561T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11
PCT/US2009/063816 WO2010056644A1 (en) 2008-11-11 2009-11-10 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS

Publications (1)

Publication Number Publication Date
HRP20120561T1 true HRP20120561T1 (hr) 2012-07-31

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120561AT HRP20120561T1 (hr) 2008-11-11 2009-11-10 Metil fenilsulfonil piperazin il h benzimidazol kao hidroksitriptaminski ligand

Country Status (41)

Country Link
US (1) US8063053B2 (OSRAM)
EP (1) EP2285784B1 (OSRAM)
JP (1) JP5087171B2 (OSRAM)
KR (1) KR101323417B1 (OSRAM)
CN (1) CN102209713B (OSRAM)
AP (1) AP2814A (OSRAM)
AR (1) AR074325A1 (OSRAM)
AU (1) AU2009314221B2 (OSRAM)
BR (1) BRPI0920682A2 (OSRAM)
CA (1) CA2740262C (OSRAM)
CL (1) CL2011001050A1 (OSRAM)
CO (1) CO6440548A2 (OSRAM)
CR (1) CR20110247A (OSRAM)
CU (1) CU24020B1 (OSRAM)
CY (1) CY1113025T1 (OSRAM)
DK (1) DK2285784T3 (OSRAM)
DO (1) DOP2011000130A (OSRAM)
EA (1) EA018369B1 (OSRAM)
EC (1) ECSP11011045A (OSRAM)
ES (1) ES2389694T3 (OSRAM)
GE (1) GEP20135805B (OSRAM)
HR (1) HRP20120561T1 (OSRAM)
IL (1) IL212213A0 (OSRAM)
MA (1) MA32788B1 (OSRAM)
ME (1) ME01129B (OSRAM)
MX (1) MX2011004996A (OSRAM)
MY (1) MY156324A (OSRAM)
NI (1) NI201100093A (OSRAM)
NZ (1) NZ592563A (OSRAM)
PE (1) PE20120026A1 (OSRAM)
PL (1) PL2285784T3 (OSRAM)
PT (1) PT2285784E (OSRAM)
RS (1) RS52381B (OSRAM)
SA (1) SA109300673B1 (OSRAM)
SI (1) SI2285784T1 (OSRAM)
SV (1) SV2011003902A (OSRAM)
TN (1) TN2011000203A1 (OSRAM)
TW (1) TWI481605B (OSRAM)
UA (1) UA100192C2 (OSRAM)
WO (1) WO2010056644A1 (OSRAM)
ZA (1) ZA201103283B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005286728A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
AU2005286790A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-CoA-desaturase (SCD)
WO2006034441A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP4958785B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
CA2953004C (en) 2014-07-08 2023-02-21 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
US12398097B2 (en) 2019-07-29 2025-08-26 Vanderbilt University WDR5-MYC inhibitors
MX2022012828A (es) * 2020-04-22 2023-01-04 Recurium Ip Holdings Llc Preparación de un degradador selectivo de receptores de estrógeno.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9700693A (es) * 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
EP0994862B1 (en) 1997-07-11 2005-06-01 SmithKline Beecham plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
PT930302E (pt) 1998-01-16 2003-07-31 Hoffmann La Roche Derivados de benzo-sulfona
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
MXPA01001464A (es) * 1998-08-10 2002-05-08 Partnership Of Michael E Garst Precursores de inhibidores de la bomba de protones.
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
AU9619301A (en) 2000-10-20 2002-04-29 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
SE0003810D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Novel compounds their use and preparations
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP2298738B1 (en) * 2000-11-02 2012-09-19 Wyeth LLC 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
CA2450245A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
WO2003026664A1 (en) 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
AU2003284142A1 (en) 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
WO2005112938A2 (en) 2004-04-13 2005-12-01 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
AU2005267798A1 (en) 2004-07-28 2006-02-09 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Also Published As

Publication number Publication date
CL2011001050A1 (es) 2011-08-19
JP2012508275A (ja) 2012-04-05
CY1113025T1 (el) 2016-04-13
NZ592563A (en) 2012-10-26
PT2285784E (pt) 2012-09-19
SV2011003902A (es) 2011-07-05
EP2285784A1 (en) 2011-02-23
KR20110075013A (ko) 2011-07-05
UA100192C2 (en) 2012-11-26
HK1158647A1 (en) 2012-07-20
NI201100093A (es) 2011-10-31
JP5087171B2 (ja) 2012-11-28
IL212213A0 (en) 2011-06-30
CN102209713B (zh) 2014-07-02
DK2285784T3 (da) 2012-07-23
ECSP11011045A (es) 2011-06-30
ME01129B (me) 2013-03-20
BRPI0920682A2 (pt) 2016-09-27
AP2814A (en) 2013-12-31
MY156324A (en) 2016-02-15
TN2011000203A1 (fr) 2012-12-17
WO2010056644A8 (en) 2010-11-18
CA2740262A1 (en) 2010-05-20
US20100120779A1 (en) 2010-05-13
CN102209713A (zh) 2011-10-05
GEP20135805B (en) 2013-04-10
EA018369B1 (ru) 2013-07-30
CU24020B1 (es) 2014-07-30
AP2011005664A0 (en) 2011-04-30
MX2011004996A (es) 2011-05-25
PE20120026A1 (es) 2012-02-12
AR074325A1 (es) 2011-01-05
CO6440548A2 (es) 2012-05-15
ZA201103283B (en) 2012-01-25
RS52381B (sr) 2012-12-31
SI2285784T1 (sl) 2012-08-31
TW201022247A (en) 2010-06-16
CR20110247A (es) 2011-06-24
KR101323417B1 (ko) 2013-10-29
CU20110101A7 (es) 2012-01-31
ES2389694T3 (es) 2012-10-30
US8063053B2 (en) 2011-11-22
EA201100696A1 (ru) 2011-10-31
EP2285784B1 (en) 2012-07-04
WO2010056644A1 (en) 2010-05-20
PL2285784T3 (pl) 2012-12-31
SA109300673B1 (ar) 2013-05-25
AU2009314221A1 (en) 2010-05-20
TWI481605B (zh) 2015-04-21
CA2740262C (en) 2013-05-28
AU2009314221B2 (en) 2012-08-30
MA32788B1 (fr) 2011-11-01
DOP2011000130A (es) 2017-04-30

Similar Documents

Publication Publication Date Title
HRP20120561T1 (hr) Metil fenilsulfonil piperazin il h benzimidazol kao hidroksitriptaminski ligand
Westerink et al. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum
JP2014526435A5 (OSRAM)
JP2012508275A5 (OSRAM)
BRPI0925343A2 (pt) Composto, composição farmacêutica, e, droga profilática ou terapêutica
NZ592961A (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
UY28940A1 (es) Derivados de quinazolina
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
BRPI0309303B8 (pt) compostos moduladores de receptores de 5ht2c, composição farmacêutica, e uso dos referidos compostos
NO20080317L (no) Substituerte tetrahydro-1H-Pyrido[4,3-B]Indoler som serotonin reseptor-agonister og antagonister
CL2011002653A1 (es) Compuestos derivados de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina), moduladores del receptor de serotonina 5-ht6; composicion farmaceutica; y su uso para el tratamiento para el tratamiento de enfermedades del sistema nervioso central, de adicion u obesidad.
EA201890402A1 (ru) 5-htрецепторные агонисты и композиции и способы применения
NO20073051L (no) Tetralin- og indanderivater og deres anvedelse
RU2011103759A (ru) Замещенные 6-(1-пиперазинил)-пиридазины в качестве антагонистов 5-нт6 рецептора
NO20015413D0 (no) Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser
TWI331919B (en) 5-ht1a receptor subtype agonist
ATE277927T1 (de) Aryl- und heteroaryl-kondensierte aminoalkyl- imidazol-derivate: selektive modulatoren der gabaa-rezeptoren
JP2015521642A5 (OSRAM)
MX2010009643A (es) Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
NZ580801A (en) Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
JOP20210020A1 (ar) معدلات عطرية غير متجانسة لمستقبل nmda واستخداماتها
DE502004011551D1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen
HRP20201152T1 (hr) Kondenzirani benzazepin za liječenje mucanja
SV2009002917A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos
NO20072972L (no) Terapeutiske pyrazolo[3,4-B]pyridiner og indazoler